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HLA class I and II in black children with hepatitis B virus- 0.1% to 15% in the general population among some
associated membranous nephropathy. regions of the world [1]. Although data on the prevalence
Background. The pathogenetic mechanisms by which indi- of HBV in Africa are neither complete nor always accu-viduals with chronic hepatitis B virus (HBV) infection develop
rate, HBV is endemic in sub-Saharan Africa [2].membranous nephropathy (MN) are probably dependent on
Hepatitis B virus (HBV) infection has been stronglyinteractions between viral, host and environmental factors; some
evidence suggests a genetic predisposition. HBVMN constitutes associated with the occurrence of membranous nephrop-
a major etiological group in black children with nephrotic syn- athy (MN), particularly in children [3, 4]. The histological
drome. We therefore explored the HLA associations in black picture reveals evidence of immunoglobulins (mainlychildren with HBVMN.
IgG) and complement deposition. Resolution of the ne-Method. Thirty black children, age range 2 to 16 years, with
phritis usually follows after antibodies to HbeAg becomebiopsy-proven HBVMN, were the subjects of the study. HBV
status was determined using third generation ELISA. HLA A, B undetectable in the serum [5, 6], and coupled with isola-
and C antigens were determined using a two-stage lymphocyto- tion of HbeAg from the glomerular basement membrane
toxic test. HLA DRB1* and DQB1* typing was done using se-
in these patients, strongly suggests a causative role ofquence-specific primers. HLA class 1 and II antigen frequencies of
HBV in the development of MN in these individuals.the study subjects were compared to controls that were randomly
chosen healthy blood donors from the same population. However, only a small minority of individuals who are
Results. HLA DQB1*0603 was increased in patients with HBV carriers develop nephropathy and the direct causal
HBVMN compared to controls (2 13.65, RR 4.3). DRB1*07 relationship of the virus in the development of nephropa-
and DQB1*02 were increased in frequency in the study subjects
thy remains a controversial issue [7]. It appears that ad-but failed to reach statistical significance. There was no signifi-
ditional factors, such as genetic and environmental ele-cant difference in the frequencies of class 1 antigens in the study
group compared to controls. ments, may predispose vulnerable individuals to develop
Conclusion. To our knowledge, this is the first report of HLA nephropathy [7]. For example, although childhood mini-
associations in black patients with HBVMN in whom Class 1 mal change nephrosis has a slight male predominance,and 11 antigens were determined using molecular methodol-
MN due to HBV has a male preponderance of 80%, evenogy. There was a high frequency of DQB1*0603 in subjects com-
higher than that reported in idiopathic MN [8, 9]. Thispared to controls, suggesting a possible genetic predisposition
to the development of HBVMN. lends support to the role of a gender-related genetic
predisposition to the development of MN.
The host immune response to HBV, which is under
Hepatitis B virus (HBV) infection continues to be one T lymphocyte control, is major histocompatibility com-
of the world’s most important diseases because of both plex (MHC)-restricted both in mice [10] and humans [11].
the number of persons infected and the associated mor- An association with non-responsiveness to the HBV vac-
bidity and mortality. Persistent infection (the carrier state) cine with HLA-DR3 has been described in Caucasians
constitutes the reservoir of infection and varies from [12, 13]. There is evidence that HLA-DR3 in Caucasians
with renal disease is associated with a MN phenotype,
regardless of cause [14]. Studies of the HLA-DRB andKey words: human leukocyte antigen, hepatitis B virus, membranous
nephropathy, genetics, nephrotic syndrome, proteinuria. DQB1 alleles in Polish patients of Caucasian descent with
HBVMN showed a significant increase in DRB1*09-Received for publication March 7, 2001
DQB1*0303 when compared to healthy controls [15]. Aand in revised form October 9, 2001
Accepted for publication November 27, 2001 study performed in twelve black South African children
with MN, 9 of whom were HBV carriers, showed a sig- 2002 by the International Society of Nephrology
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Table 1. Oligonucleotide primers used in the study
Primer Sequence Positiona Sizeb
Outer primers 1730() 5-CTGGGAGGAGTTGGGGGAGG 1730–1747 314 bp
2043() 5-CAATGCTCAGGAGACTCTAAGG 2043–2021
Inner primers 1763() 5-GGTCTTTGTACTAGGAGGCTG 1763–1783 204 bp
1966() 5-GTCAGAAGGCAAAAACGAGAG 1966–1946
Symbols are: (), sense; (), antisense.
a Denotes nucleotide position of hepatitis B virus ayw (GenBank accession no. V00866) where the EcoRI cleavage site is position 1 [16]
b Size of the polymerase chain reaction product in base pairs
nificantly increased frequency of HLA Bw21. The DR anti- Viral studies
gens in the latter group of patients were not typed [16]. Hepatitis B status was determined using third genera-
Many reported cases of HBVMN have come from tion enzyme-linked immunosorbent assay (ELISA; Aus-
South Africa; including our own large series of black pa- zyme Monoclonal; Abbott Laboratories, North Chicago,
tients with HBVMN [6] and a similar study from Cape IL, USA). HCV was determined using a microparticle
Town [9]. Therefore, we performed molecular phenotyp- enzyme immunoassay (MEIA) for the detection of anti-
ing of the HLA complexes to investigate a possible ge- bodies to the hepatitis C virus (Abbot ImxHCV version
netic predisposition to the development of MN in black 3.0). HIV testing was done using an ELISA method
children who were HBV carriers, all of whom had ne- (Abbot recombinant HIV1-2, 3rd generation EIA) and
phrotic syndrome. if positive, confirmation was done using an immuno-
fluorescence assay (Virion).
METHODS
Determination of genotype
Patients
To determine the genotype the pre-core region of
Thirty children, age range 2 to 16 years, with biopsy- HBV DNA extracted from serum samples was sequenced
proven HBVMN, were the subjects of this study con- directly from polymerase chain reaction (PCR products).
ducted at King Edward VIII Hospital, Durban in Kwa- The PCR amplification mixture (5 to 10 L) was pre-
Zulu/Natal, South Africa during the period of 1995 to treated with two hydrolytic enzymes: exonuclease I (10.0
1998. Clinical details of these subjects have been the U/mL) to remove sticky ends and primers, and shrimp
subject of a previous publication [6]. All were black and alkaline phosphatase (2.0 U/mL) to remove nucleotides
came from semi-urban or rural communities. None were (Sequenase PCR product sequencing kit; United States
siblings or related in any way and none had received
Biochemicals, Cleveland, OH, USA). Enzymatic pre-
HBV vaccine. Informed consent for phlebotomy was ob-
treatment was carried out at 37C for 15 minutes, andtained from the child’s parent or guardian. Fifteen milli-
enzymes were inactivated by heating to 80C for an addi-liters of peripheral blood was obtained for HLA typing,
tional 15 minutes in a thermal cycler.viral studies and assessment of renal function. The con-
Sequencing was carried out using the Sequenase PCRtrol subjects were randomly chosen healthy blood donors
kit, but with modifications of the methods by Casanovafrom the same province in South Africa. All were black
et al [18, 19]. The annealing mixture contained 0.5 pmolsubjects: N  3176 in the HLA A and B groups, N 
DNA (10 to 90% of the amplified sample, depending on1739 in the HLA C group, and N  490 in the HLA
the PCR yield), 10 pmol primer (1763 and 1966R; Ta-DR and DQ groups. Fifty-two percent of these healthy
ble 1) and BQW in final 10 L volume. The sample wascontrols were males. The study was approved by the
denatured at 99C and then immediately placed in anEthics and Professional Standard Subcommittee of the
ice water bath for five minutes. The labeling reactionFaculty of Medicine, University of Natal.
was carried out using 101 dilution of labeling mix and
HLA typing 5 Ci 35S-dATP for two minutes. Termination was carried
out at 40C for five minutes. The sequences were ana-The HLA A, B, and C antigens were determined using
lyzed on an 8% polyacrylamide gel in glycerol toleranta two-staged lymphocytotoxic test [17]. These antigens
buffer and autoradiographed using Kodak film (X-omat;were identified with 180 antisera, which consisted of local
Eastman Kodak, Rochester, NY, USA; Sigma, St. Louis,sera and sera requested for use by the International
MO, USA). Mutations were recorded only when theyHistocompatibility Workshops and sera exchanged with
were detected in both the forward and reverse sequences.other laboratories worldwide. The sera were verified by
use in parallel with the International Workshop sera.
HistologyDNA was extracted from 10 mL of ACD blood using a
Hepatitis B virus membranous nephropathy was de-Genomix Kit. HLA DRB1* and DQB1* typing was done
using sequence-specific primers (SSP) [18]. fined by examination of light and electron microscopy,
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Table 3. HLA B antigen frequencies in subjects and controlsTable 2. HLA A antigen frequencies in subjects and controls
Random Patients Controls Patients
RelativeRelative
N3176 % N30 % 2 risk N3176 % N30 % 2 risk
B7 685 21.5 9 30.0 1.25 1.6A1 238 7.5 0 0.00 2.43 0.0
A36 52 1 1 3.3 0.53 2.1 B8 408 12.8 2 6.6 1.02 0.5
B13 133 4.1 1 3.3 0.05 0.8A2 765 24 8 26.6 0.12 1.1
A3 394 12.4 2 6.6 0.90 0.5 B14 202 6.3 2 6.6 0.00 1.1
B18 150 4.7 2 6.6 0.25 1.4A11 2 0.0 0 0.0 0.02 0.0
A23 519 16.3 4 13.3 0.20 0.8 B22 1 0.0 0 0.0 0.01 0.0
B27 16 0.5 0 0.0 0.15 0.0A24 198 6.2 2 6.6 0.01 1.1
A25 26 0.8 0 0.0 0.25 0.0 B35 254 8.0 1 3.3 0.88 0.4
B37 2 0.0 0 0.0 0.02 0.0A26 332 10.4 5 16.6 1.22 1.7
A34 385 12.1 7 23.3 3.48 2.2 B38 44 1.3 0 0.0 0.42 0.0
B39 66 2.0 1 3.3 0.23 1.6A28 708 22.2 7 23.3 0.02 1.1
A29 428 13.4 5 16.6 0.26 1.3 B41 42 1.3 0 0.0 0.40 0.0
B42 595 18.7 7 23.3 0.41 1.3A74 41 1.2 2 6.6 6.49 5.5
A30 1005 31.6 13 43.3 1.87 1.7 B44 508 15.9 10 33.3 6.60 2.6
B45 269 8.4 2 6.6 0.12 0.8A31 93 2.9 0 0.0 0.90 0.0
A32 71 2.2 0 0.0 0.69 0.0 B47 2 0.0 0 0.0 0.02 0.0
B48 3 0.0 0 0.0 0.03 0.0A33 86 2.7 1 3.3 0.04 1.2
A43 19 0.6 0 0.0 0.18 0.0 B50 24 0.7 1 3.3 2.55 4.5
B51 45 1.4 2 6.6 5.67 5.0A66 3 0.0 0 0.0 0.03 0.0
Xa 987 31.0 3 10.0 6.19 0.2 B52 4 0.1 0 0.0 0.04 0.0
B53 51 1.6 0 0.0 0.49 0.0Total 3176 100.00 30 100.00
B5I 0 0.0 0 0.0
a Only one antigen detected B57 260 8.1 3 10.0 0.13 1.2
B58 937 29.5 8 26.6 0.11 0.9
B60 6 0.1 0 0.0 0.06 0.0
B61 0 0.0 0 0.0
and by immunofluorescent staining of kidney biopsy B62 30 0.9 0 0.0 0.29 0.0
B63 29 0.9 0 0.0 0.28 0.0specimens. HBVMN has classical subepithelial deposits,
B70 908 28.5 7 23.3 0.40 0.8but with varying degrees of mesangial involvement that
Ya 632 19.90 2 6.6 3.28 0.3
may include proliferation [20, 21].
Total 3176 200.00 30 200.00
a Only one antigen detectedStatistical analysis
Chi-square was used to determine the significance of
both susceptibility and protective HLA alleles in the one patient had normal renal function. None had sero-
study group of patients and was compared to the fre- logical evidence of hepatitis C virus or human immuno-
quencies in population-based controls of black subjects. deficiency virus (HIV) infection.
Corrected P values were obtained by multiplying by the The number and phenotypic frequencies of the HLA
number of alleles tested for at each locus. Haplotypes A, B, C, DRB and DQB1 alleles in children with HBVMN
were estimated according to the method of Mattiuz et and population based controls are shown in Tables 2
al [22]. The significance of linkage disequilibrium was to 6. A statistically significant difference was detected in
measured by the delta value (the difference between the Class II antigens: HLA DQB1*0603 was increased
observed and expected frequencies) divided by the stan- in patients with HBVMN compared to controls (2 
dard error of the estimated haplotype frequencies. 13.65, Pc  0.001; RR 4.3). Six (28.6%) of 21 males and
3 (33.3%) of 9 females were HLA DQB1*0603 positive.
There were no significant differences in frequency be-RESULTS
tween males and females positive for DQB1*0603. HLA
All thirty patients had nephrotic syndrome diagnosed DRB1*07 and DQB1*02 were increased in frequency in
in accordance with criteria used by the International the study subjects when compared to controls but failed
Study of Kidney Diseases in Children [23] and were in to reach statistical significance. The HLA DRB1*07 and
relapse at the time of the study. Twenty-eight of the DQB1*02 antigens were in linkage disequilibrium in
thirty patients were both HbsAg and HbeAg positive; both patients and in controls. There were no significant
two were only HbsAg positive. Twenty-one (70%) were differences in the frequencies of class I antigens in the
males. All were genotype A. Although ten had evidence study group compared to controls.
of mildly raised liver enzymes (gamma glutamyl trans-
ferase and aspartamine alanine transferase), none had
DISCUSSIONclinical evidence of chronic liver disease and liver biopsy
was not performed in any of the patients. Twenty patients Nephrotic syndrome in children has been shown pre-
viously to be associated with HLA class II alleles basedhad mild hypertension at presentation [24] and all except
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Table 6. HLA DQ antigen frequencies in subjects and controlsTable 4. HLA C antigen frequencies in subjects and controls
Controls Patients Controls Patients
RelativeRelative
N1739 % N30 % 2 risk DQB N490 % N30 % 2 risk
05 127 25.9 3 10.0 3.82 0.3Cw1 12 0.6 0 0.0 0.21 0.0
Cw2 309 17.7 2 6.6 2.51 0.3 06 22 4.4 1 3.3 0.09 0.7
0601 2 0.4 1 3.3 4.22 8.4Cw3 260 14.9 2 6.6 1.60 0.4
Cw4 345 19.8 8 26.6 0.86 1.5 0602 140 28.5 9 30.0 0.03 1.1
0603 44 8.9 9 30.0 13.65 4.3Cw5 16 0.9 0 0.0 0.28 0.0
Cw6 612 35.1 10 33.3 0.04 0.9 0604 77 15.7 2 6.6 1.80 0.4
02 153 31.2 13 43.3 1.91 1.7Cw7 721 41.4 15 50.0 0.89 1.4
Cw8 91 5.2 1 3.3 0.22 0.6 0301 95 19.3 5 16.6 0.13 0.8
0302 26 5.3 0 0.0 1.68 0.0Cw17 312 17.9 6 20.0 0.08 1.1
Z 800 46.0 16 53.3 0.64 1.3 0303 5 1.0 1 3.3 1.33 3.3
0304 24 4.9 1 3.3 0.15 0.7Total 1739 200.00 30 200.00
03 19 3.8 1 3.3 0.02 0.9
04 102 20.8 6 20.0 0.01 1.0
‘Q’ 144 29.3 8 26.6 0.10 0.9
Table 5. HLA DR antigen frequencies in subjects and controls Total 490 100.00 30 100.00
Controls Patients
Relative
DRB N490 % N30 % 2 risk
HLA DR7 has been frequently detected in relation
01 37 7.5 2 6.6 0.03 0.9
to HBV immune reactions. DR7 is most often associated15 90 18.3 9 30.0 2.48 1.9
16 3 0.6 0 0.0 0.18 0.0 with DQ2. Earlier studies have shown that in Caucasians,
0301 93 18.9 4 13.3 0.59 0.7 there is a low responsiveness to HBV associated with
0302 125 25.5 9 30.0 0.30 1.3
DR7. The initial reports of an HLA genotype to hypo-04 52 10.6 0 0.0 3.54 0.0
11 144 29.3 5 16.6 2.24 0.5 responsiveness to HBV vaccine demonstrate an increased
12 54 11.0 1 3.3 1.77 0.3 incidence of DR7. However, none of these studies report13 148 30.2 14 46.6 3.57 2.0
on the DQ associations [33, 34]. A report from Qatar in14 24 4.9 3 10.0 1.49 2.2
07 75 15.3 8 26.6 2.72 2.0 Arabs showed significantly increased levels of DR7 in
08 24 4.9 0 0.0 1.54 0.0 subjects with persistent HBV infection [35], although09 8 1.6 1 3.3 0.48 2.1
again there were no reports of associated DQ antigens.10 20 4.0 0 0.0 1.27 0.0
D 83 16.9 4 13.3 0.26 0.8 Recently, DRB1*0701-DQB1*0202 in Caucasians has
Total 490 100.00 30 200.00 been shown to be associated with a response to the hepa-
titis coat antigen [36].
However, our study in black children with HBVMN
failed to show any significant associations with DRB1*on serological and DNA typing [25–32]. Such studies
0701 or DQB1*0202. Although previous studies in blackemphasize the role of genetic factors in the development
patients did not include the class II antigens, inferencesof idiopathic NS in children of Caucasian, Chinese and
can be made on the basis of linkage disequilibrium. TheseJapanese descent. In children of Polish descent, HBVMN
antigens are not in linkage disequilibrium with DQB1*was associated with DQB1*0303. In the only study of
0603 in blacks in South Africa, which suggests that moreHLA associations in HBVMN in black children in Dur-
than one allele in the major histocompatibility group ofban, South Africa, the frequency of Bw21 in black chil-
genes may be involved in the development of HBVMN.dren with MN compared to healthy controls was signifi-
In another study done in Caucasians, DQB1*0602 andcantly increased (15 vs. 1%, respectively, Pc0.04; relative
DQB1*0603 were associated with a response to immuni-risk 22.1). However, only eleven of these children were
zation with HbsAg [37]. These findings suggest that eth-tested for HBV; nine were positive. The number of chil-
nic differences also may play a role in HLA associationsdren negative for HBsAg was too few to allow meaning-
ful comparison in HLA frequencies between the two to HBV antigens.
The results of the current study reinforce the conceptgroups [16]. This small study did not evaluate the DR and
DQ antigens. Therefore, this is most likely a gratuitous that within a specific ethnic community there is a group
that is genetically susceptible to the development of MNfinding. Also, when the results of the findings in the previ-
ous study [16] are combined with the present study, there following chronic infection by HBV. The degree of sus-
ceptibility might vary between populations, dependingwere no statistically significant differences (7% in study
subjects vs. 2.7% in controls; P 	 0.05). To our knowl- on the frequency of the HLA-linked susceptibility loci.
Since the linkage disequilibrium pattern for alleles at HLAedge, this is the first report of HLA associations in black
children with HBVMN in which both class I and II anti- loci differs among populations, susceptibility to HBVMN
may be expected to be associated with antigens othergens have been studied using molecular methodology.
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than DRB1*0701 and/or DQB1*0202 in other popula- reports of genotypic associations of HBV with particular
disease manifestations. Thus, it is unlikely that viral geno-tions, as reported [16, 37].
To date, HLA DQB1*0603 has not been found to be type plays a major role in the development of MN.
HLA association in black patients with HBVMN inassociated with any other diseases in the black popula-
tion. Thus, it is possible that the significant increase noted whom class I and II antigens were determined using
molecular methodology have not been reported pre-in the DQB1*0603 in HBVMN patients is secondary
to the low incidence of the DQB1*0603 in our control viously. Our study shows a significantly high frequency
of DQB1*0603 in children with HBVMN compared topopulation (8.98%). Alternatively, this may be a chance
finding, but without further studies this remains a possi- controls and suggests a possible genetic predisposition
to the development of this disease. However, the lackble explanation.
The study subjects are patients with HBV carriage of association between DQB1*0603 and HLA DRB1*07
(which is associated with a low response to HBV in Cauca-with associated MN, whereas the controls have neither.
It is possible that DQB1*0603 may predispose to HBV sians) or any of the other immune response genes, to-
gether with the preponderance of HBVMN in males, sug-carriage only, as opposed to predisposing to the develop-
ment of HBVMN, as only a small percentage of subjects gests that genetic factors other than HLA may play a
role in the development of HBVMN.who are carriers of HBV develop MN (7%). As part of
our larger study (which is the subject of another report),
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